## 4 Poster Presentations
### P-02. Dried Blood Spot Contamination--An Underestimate Risk in Newborn Screening
In test accuracy studies, positive test results have to be confirmed by genetic analysis and follow-up for negative test results has to be reported. Otherwise--in the case of verification of only positive testers--no information on sensitivity and specificity can be given. If feasible and useful, single study results are summarized in meta-analyses. Results: Preliminary results of the benefit assessment are expected to be published in summer 2016. _P-05. A Simple Method to Overcome the \"Floating Disc Problem\" Using the GALT-Assay on the PerkinElmer GSP_  
[PERSON] 1,2,* and [PERSON] 1,2  
1 Swiss Newborn Screening Laboratory, University Children's Hospital, Zurich, Switzerland  
2 Children's Research Center, Zurich, Switzerland  
* Correspondence: [PERSON]; Tel. : +41-44-266-7732; Fax: +41-44-266-8110  
The Perkin Elmer Genetic Screening Processor (GSP)TM is a fully automated system for the processing of immunoassay for TSH, 17-OHP, IRT, biotinidase, and total T4, as well as enzymatic assays for total galactose and galactose-1-phosphate uridyltransferase (GALT) from dried blood spots (DBS). The system, however, has one draw back: It can not transfer samples from one microtiter plate to another one. While this is not a problem with immunoassay, it makes enzymatic assays more problematic, because dried blot spots have to remain in the wells and can cause significant signal quenching, thereby reducing sensitivity, or they can increase fluorescence intensity, when the extracted spots are floating on the surface of the reacting mixture. The latter can cause false negative results, when GALT activity is measured for galactosaemia screening. To overcome this problem, GSP includes an additional measurement step to check for floating disks, leading to prevention of the affected measurements. However, this causes a secondary problem in this totally closed system. We detected floating disk signals in approx. 0.5% of all screening, as well as quality control samples, which had to be repeated. In some cases even a second sample had to be requested, because floating disks were detected again in the 2 nd, 3 rd, and 4 th repeat assays. To overcome this problem, we developed a method of employing a second-tier measurement on a victor fluorescence reader. Using this second-tier measurement made all repeat measurements unnecessary. _P-06. Interim Results of a Pilot Newborn Screening Program in Nepal_  
[PERSON] 1,2,* and [PERSON] 3\({}^{1}\) Swiss Newborn Screening Laboratory, University Children's Hospital, Zurich, Switzerland  
\({}^{2}\) Children's Research Center, Zurich, Switzerland  
\({}^{3}\) Kathmandu Medical College and Teaching Hospital, Kathmandu, Nepal  
\({}^{\star}\) Correspondence: [PERSON]; Tel. : +41-44-266-7732; Fax: +41-44-266-8110  
Over the last few years, there were numerous countries that celebrated 50 years of newborn screening (NBS), and, within the next few years, more will follow. The International Society for Neonatal Screening (ISNS) will also celebrate at the conference in The Hague: \"ISNS silver jubilee--25 years of sharing knowledge globally\". Additionally, while Switzerland celebrated its 50 years NBS anniversary, the Kathmandu Medical College and Teaching Hospital and the Children's Hospital in Zurich started their collaboration with a pilot NBS program for Nepal. This program is supported Nepal Health Research Council (NHRC), and will be comprised of 5000 dried blood samples from Nepal in the first phase. We can present the interim results of the first year, from March 2015 to March 2016, of this pilot study. Until now, 3786 samples have been tested. Within this cohort, we could detect one case with congenital hypothyroidism and one case with Cystic fibrosis. At the moment, we are planning to extend the pilot to a total number of 10,000 samples, and explore the possibility to further transfer knowledge and methodology to Nepal. P-07.